FDAnews Drug Daily Bulletin
Oct. 9, 2012
| Vol.
9 No.
198
The FTC Thursday asked the Supreme Court to take up and overturn an 11th Circuit Court’s decision that upheld the legality of reverse patent settlements between branded drug makers and generic competitors.
Drugmakers’ quality control checklists make it difficult for inspectors to interpret manufacturing failures and foster a true understanding of mistakes, regulators and industry officials say.
A sharp increase in exaggerated or misleading comparative claims in drug advertisements has the FDA analyzing the issue and considering guidance on it to help stop the violations.
Pfizer, the India unit of U.S. drugmaker Pfizer, will challenge the country’s patent office for revoking a patent for its cancer drug Sutent (sunitinib).
An investigational agent may provide neuroprotection to patients undergoing endovascular repair of an intracranial aneurysm, a Phase II trial showed.
Pharma major Dr Reddy’s Laboratories said it has expanded its manufacturing operations in the United Kingdom.
Like any patient at risk of a heart attack, Kennedi Thompson has been counseled by her doctor to eat a low-fat diet and take prescription statins to reduce her cholesterol.
The Supreme Court asked the central government to provide details of clinical trials being conducted throughout the country, their side effects and deaths, if any.
Heidi Clow was on a health kick.
|
Register Now
Archives
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews
All rights reserved. Do not duplicate or redistribute in any form.